DIAGNOS Announces Amendment to Convertible Debentures
Mar 31, 2025 - financialpost.com
Diagnos Inc., a Canadian corporation specializing in early detection of critical health issues using AI technology, announced an amendment to the terms of its unsecured convertible debentures. The amendment involves extending the maturity date from March 25, 2025, to March 25, 2026, and increasing the yearly interest rate from 8% to 10% for the extended period. All other provisions of the debentures remain unchanged, and the amendment is subject to TSX Venture Exchange acceptance and formal documentation execution.
Diagnos aims to enhance diagnostic accuracy and improve patient outcomes globally by leveraging AI technology. The company is publicly traded and focuses on detecting critical eye-related health problems. The press release emphasizes that all financial figures are in Canadian dollars and includes a cautionary statement regarding forward-looking information. Additional information about Diagnos can be found on their website and SEDAR.
Key takeaways:
DIAGNOS Inc. plans to amend the terms of $120,000 of unsecured convertible debentures, extending the maturity date to March 25, 2026.
The yearly interest rate for the debentures will increase from 8% to 10% for the extended period.
The amendment is subject to TSX Venture Exchange acceptance and formal documentation execution.
DIAGNOS is focused on early detection of critical eye-related health problems using AI technology.
